Zavegepant nasal spray for the acute treatment of migraine: A meta analysis.

ABSTRACT:

Background

Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acute treatment of migraine - a prevalent disease leading to disability and economic burden. The meta-analysis aims to quantify the efficacy of Zavegepant compared to standard care or placebo in achieving pain freedom, freedom from most bothersome symptoms (MBS), sustained pain freedom, and pain relapse at 2 to 48 hours.

Methods

Databases and registers were systematically searched to identify relevant clinical trials. Two independent reviewers used a standardized data extraction form to collect relevant data on primary and secondary outcomes. Statistical analysis was performed in RevMan 5.4 software. The efficacy of Zavegepant was compared to placebo using odds ratios (OR) w

SUBMITTER: Waqas M 

PROVIDER: S-EPMC10615551 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature